**Technology Advisory Committee B Interests Register**

**Renal cell carcinoma Pathways Pilot [ID6186]**

**Publication Date: Tbc.**

| Name | Role with NICE | Type of interest | Description of interest | Interest  declared | Interest  ceased | Comments |
| --- | --- | --- | --- | --- | --- | --- |
| Dawn Lee | EAG | Indirect - Financial | Provided private consultancy services to Neuraxpharm, Ascenian Consulting and Market Research, unrelated to possible intervention, comparators, intervention or comparator companies in this RCC appraisal.  Lumanity:  Was previously employed as the Chief Scientific Officer at Lumanity until September 2022. Work from December 2021 included projects and companies unrelated to possible intervention, comparators, intervention or comparator companies in this RCC appraisal.  A very small shareholder in Value Demonstration Group (who are the holding company for Lumanity),  Fiecon Ltd:  A family member owns Fiecon. However, not a shareholder of Fiecon.  A member of Fiecon's strategic council from Nov 2023 (receiving financial income). Not specifically related to RCC.  Provides mentoring support (receiving financial income).  Not specifically related to RCC.  Provide consultancy services to Fiecon on several projects, including one topic for Eisai, unrelated to possible intervention, comparators, intervention or comparator companies in this RCC appraisal. | 01/02/2024 | N/A | It was agreed that Dawn’s conflicts would not prevent her from being part of the EAG. |
| Darren Burns | EAG | Indirect - Financial | Employed as an Analyst at Delta Hat Limited from September 2022. Principle Health Economist at Lumanity / Bresmed until September 2022.  From December 2021, worked on projects and for companies unrelated to possible intervention, comparators, intervention or comparator companies in this RCC appraisal. Consultancy services (financial) for Pfizer on a technology unrelated to RCC, and Servier on Multilocular cystic renal cell carcinoma (MCRCC) which is not considered a possible comparator in this appraisal.  Scottish Medicines Consortium on multiple projects. | 01/02/2024 | N/A | It was agreed that Darren’s conflicts would not prevent him from being part of the EAG. |
| David McAllister | TAC B committee member | Non-Financial Professional & Personal Interests | Research involves secondary analysis of trial data provided by competitors via a trial data sharing platform. | 18/01/2024 | N/A | It was agreed that David’s conflicts would not prevent him from being part of the committee. |
| Dr Balaji Venugopal | Clinical Expert | Indirect | Principal investigator for Ipsen, BMS, MSD sponsored clinical trials | 06/03/2023 | N/A | It was agreed that Dr Venugopal’s conflicts would not prevent him from providing expert advice to of the committee. |
| Geraldine Fox | Patient Expert | Indirect - Financial | Kidney Cancer UK conflicts:  Pfizer: £25,00 competitive grant to produce an information booklet and referral guide for GPs  EU: £2,500 contribution to cost of service quality audit  Ipsen £2,500 contribution to cost of service quality audit  Ipsen £2,000 contribution to disease awareness publicity in Kidney Cancer Awareness Week | 05/07/2023 | N/A | It was agreed that Geraldine’s conflicts would not prevent her from providing expert advice to of the committee. |
| Dr Veline L’Esperance | Committee Member | Financial | As Research Director for a primary acre organisation, we often undertake trials on behalf of Pharmaceutical companies. None of these trials are in Renal Cell carcinoma. However, some of the companies we collaborate with include: Novartis, Pfizer and Roche |  |  | It was agreed that Veline’s conflicts would not prevent her from being part of the committee. |